Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Projected Long-Term Survival High for Patients with Advanced Non–Small-Cell Lung Cancer Treated with Pembrolizumab

TOP - May 2017, Vol 10, No 2 - Lung Cancer

Orlando, FL—Durability of benefit (ie, the possibility for sustained remission in patients with previously incurable disease) is already one of the hallmarks of immunotherapy. According to a recent statistical analysis, however, this durability even exceeded expectations.

Based on data from multiple KEYNOTE clinical trials, Matthew D. Hellmann, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, estimates that ≤25% of patients with advanced non–small-cell lung cancer who received pembrolizu­mab will achieve long-term survival. When compared with a long-term survival rate of just 3% to 4% for patients who received chemotherapy, these findings underscore the “remarkable step forward” made with immunotherapy, Dr Hellmann noted.

“We’re cautious to use these sorts of words, but these outcomes really do start to approach the concept of cure for patients with advanced cancer. These aren’t just numbers on a curve or dots on a plot; these are patients that we see in the clinic who are continuing to do well years after being given pembrolizumab,” he said.

As Dr Hellmann reported at the 2017 Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium, whereas cytotoxic chemotherapy or tyrosine inhibitors provide some meaningful anticancer responses, progression invariably occurs. With the advent of immunotherapies, however, the survival curve for patients with several types of advanced cancers has fundamentally changed.

“Using conventional modeling, in which we assume that everyone progresses, the proportion of patients with long-term survival is potentially zero. In the context of immunotherapy, however, progression and death is not necessarily inevitable, and long-term survival models must consider the possibility of a plateaued survival when estimating outcomes further out,” said Dr Hellmann.

Using medium-term survival data from KEYNOTE-001 and KEYNOTE-010 studies, in which previously treated patients with PD-L1–positive non–small-cell lung cancer were given pembrolizumab, the investigators projected the percentage of patients who would achieve long-term survival.

“Our approach was to take an initial estimate of long-term survival in patients treated in KEYNOTE-001 and then independently examine data from KEYNOTE-010 to validate the reproducibility of that estimate,” Dr Hellmann explained.

With this model, based on KEYNOTE-001 data, it was estimated that approximately 25.4% of patients receiving pembrolizumab therapy would survive long-term. Further analysis of KEYNOTE-010 cutoff data, which included 6 additional months of patient follow-up, showed a long-term survival estimate of approximately 21.5%. By contrast, docetaxel chemotherapy has an estimated long-term survival rate of 3% to 4% in the same patient population.

“The lives and the expectations of these patients has remarkably changed,” said Dr Hellmann, who emphasized that this is just the beginning of research into immunotherapy’s survival benefit.

“We’ve got a lot of work to do in understanding with precision who these people are in the tail of the curve so that we can get them the right therapy from the start,” he concluded.

Related Items
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Educating NSCLC Patients on Adverse Event Management
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T), Cathy Simmons, RN, BSN, ONN-CG(T), Lauren Welch, MSN, NP-C, AOCNP
Videos published on July 8, 2021 in Interview with the Innovators, Lung Cancer, Adverse Events
Addressing Lung Cancer Screening Disparities in LGBT Populations
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Analysis Identifies EGFR as Most Common Mutation in Women with Lung Cancer and No Smoking History
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Cemiplimab Potential New Treatment Option for Patients with Advanced NSCLC and PD-L1 ≥50%
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
“Astonishing Results” Seen with First-Line Lorlatinib for the Treatment of ALK-Positive NSCLC
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Last modified: July 22, 2021